Joseph Jung Hyuk Yim

Joseph Jung Hyuk Yim is an associate in the firm’s Business Law department. He joined Goodwin in 2020.

Joseph represents public and private companies in all stages of maturity in the technology and life sciences industries. He counsels clients on a wide array of corporate matters, including entity formation, venture capital financings, public securities offerings, mergers and acquisitions, securities law compliance, and strategic transactions.

Joseph's representative matters include:

Capital Markets Transactions

• Achilles Therapeutics in its $175.5 million initial public offering
• Kaleido Biosciences in its $69.4 million follow-on offering 
• BeiGene in its US $3.5 billion (RMB 22.2 billion) initial public offering in STAR Market of the Shanghai Stock Exchange

Mergers and Acquisitions

• Charlesbank in its $1.1 billion acquisition of MB2 Dental Solutions
• LEXEO Therapeutics in its acquisition of Stelios Therapeutics

Venture Capital Financing Transactions

• Atlast Food in its $40 million Series A financing transaction
• Skyhawk Therapeutics in its $130 million Common Stock financing transaction
• Curie Therapeutics on its $75 million Series A financing transaction
• Beta Bionics on its $57 million Series C financing transaction
• Eventide Asset Management in its investment of Metagenomi’s $175 million Series B financing transaction
• Vida Ventures on its $25 million investment of Affini-T Therapeutics’ $175 million Series A/B financing transaction

Joseph was a summer associate at Goodwin in 2019.

• Co-Author, “Leveraging Child Nutrition Reauthorization To Reduce Food Waste,” Harvard Food Law and Policy Clinic, May 2021